Viewing nowCombinationJBICA Tablet 10/40mg
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
BIVOCON Pharmaceutical Co., Ltd.

MFDS item code 201404714 · Approved 2014.10.15 · Insurance code 658202690
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively control the blood pressure of patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment. (See section 2, “Patients who should not receive this drug,” under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. Blood pressure should be monitored closely and more frequently in elderly patients.
∘Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.
This drug may cause serious harm to the fetus and newborn if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in individuals with allergies to any ingredients in this drug, those who are pregnant or breastfeeding, patients with severe liver impairment, those undergoing dialysis, or in shock. Patients with fluid or salt depletion or those with hypotension should be closely monitored at the beginning of treatment as their blood pressure may drop too low; appropriate treatment should be provided if necessary. Since there is a risk of rapid blood pressure drop due to vascular dilation, careful administration is required for patients with severe aortic stenosis or obstructive coronary artery disease. In patients with heart failure, careful use is warranted, and renal function should also be closely monitored in patients with impaired renal function. Patients with impaired liver function may experience delays in metabolism of this drug, thus requiring dosage adjustment and careful monitoring. This drug can cause various side effects, including dizziness, headache, hypotension, edema, gastrointestinal disturbances, skin rashes, and myalgia. In particular, if blood pressure drops too low or heart rhythms become irregular, consultation with a healthcare professional should be sought immediately. This drug may interact with other medications, so it is important to inform healthcare professionals of any current medications. In particular, taking grapefruit juice may enhance blood pressure-lowering effects excessively, so it is best to avoid it. It is generally advised not to take this drug during pregnancy, and if planning to become pregnant or after pregnancy confirmation, consultation with a physician is essential. If breastfeeding, it is necessary to consider stopping breastfeeding or changing medications, as this drug can be transmitted in breast milk and may affect the infant. It is recommended not to use this drug in children under the age of 18 as safety and efficacy have not been established. Elderly individuals may have reduced renal and liver function and should start at a low dose and carefully adjust the dosage. In case of overdose, severe hypotension and vasodilation may occur and immediate emergency treatment is needed. This drug should be stored in a tightly sealed container, protected from direct sunlight and moisture, and kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This drug must be stored in a sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C. Proper storage will ensure the drug's effectiveness.
Round, reddish-brown film-coated tablet
30 tablets (10 tablets/Alu-Alu*3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
BIVOCON Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.